StocksMedium•13 November 2026•
1 min read
Roche Gazyva Receives Positive EU Committee Opinion for Lupus Nephritis Treatment
Key Facts
1Roche received a positive opinion from the EU's Committee for Medicinal Products for Human Use (CHMP) for Gazyva in treating lupus nephritis.
Roche received a positive opinion from the EU's Committee for Medicinal Products for Human Use (CHMP) for the use of Gazyva in treating lupus nephritis. Investing.com reported that the recommendation covers the use of obinutuzumab for patients with active proliferative lupus nephritis, moving the treatment closer to full marketing authorization within the European Union.
The regulatory recommendation is based on clinical data demonstrating the efficacy of Gazyva in addressing this specific autoimmune kidney condition. In equity markets, RHHBY closed at $60.5 on November 12, 2026, having traded between a low of $60.47 and a high of $60.98 during that session.